Erica Andreozzi

Erica Andreozzi, PhD, serves as Associate Director of Clinical Development at Eisai US, focusing on the clinical development of therapies for Alzheimer's Disease since September 2021. Previously, Erica held multiple roles within Novartis, including Neuroscience Medical Science Liaison and Clinical Development Director, where responsibilities included analyzing clinical trial data, supporting publication planning, and leading biomarker development initiatives. Erica's earlier experiences include work at Eli Lilly and Company as a Medical Science Liaison in the Neurodegenerative/Pain area and postdoctoral positions at the University of Melbourne and Kings College London, where significant research on neurotoxicity and Alzheimer’s diagnostics was conducted. Erica earned a PhD in Biomedical Engineering from the University of California, Davis, and a BS in Biomedical Engineering from Bucknell University.